Trial · NCT02306161
Outcomes14
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
1 to 14 of 14
Download this page as JSON| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Event-free Survival | 5 years after enrollment | Only eligible patients are considered in the calculation of this outcome measure. | percent probability of participants | NUMBER |
| SECONDARY | Overall Survival | 5 years after enrollment | Only eligible patients are considered in the calculation of this outcome measure. | Percent Probability | NUMBER |
| SECONDARY | Frequency of Toxicity-events | Up to 202 days | Only eligible patients who received at least one dose of assigned protocol therapy are considered in the calculation of this outcome measure. Five hundred twenty-seven (527) reporting periods were contributed by patients enrolled on Regimen A; Five hundred seventy-six 576 reporting periods were contributed by patients enrolled on Regimen B. | Reporting Periods | NUMBER |
| OTHER_PRE_SPECIFIED | Serum IGF Pathway Component and Tissue Protein, Deoxyribonucleic Acid (DNA), and Ribonucleic Acid Markers | Up to 10 years | |||
| OTHER_PRE_SPECIFIED | Tumor Cell Surface IGF-1R Expression | Up to 307 days | |||
| OTHER_PRE_SPECIFIED | Germline Polymorphisms in EGFR | Up to 10 years | |||
| OTHER_PRE_SPECIFIED | EWS Translocation | Up to 10 years | |||
| OTHER_PRE_SPECIFIED | Circulating Tumor DNA (ctDNA) Testing | Up to 202 days | |||
| OTHER_PRE_SPECIFIED | Serial Genomic Profiling | Up to 307 days | |||
| OTHER_PRE_SPECIFIED | Occurrence of Sinusoidal Obstructive Disease (SOS) Associated With the Addition of Ganitumab to VDC/IE | Up to 202 days | |||
| OTHER_PRE_SPECIFIED | Frequency of Resolution of Bone Marrow Metastases | Up to 84 days | |||
| OTHER_PRE_SPECIFIED | Frequency of Toxicity Events During Ganitumab Maintenance | Up to 307 days | |||
| OTHER_PRE_SPECIFIED | Trough Levels of Serum Ganitumab | Up to 15 days | |||
| OTHER_PRE_SPECIFIED | Proportion of Patients Who Successfully Receive Planned Stereotactic Body Radiotherapy (SBRT) | 202 days |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02306161/outcomes